ORIGINAL ARTICLE

Cytogenetic mutation in a family with sickle-cell beta-thalassemia in North Sumatera, Medan, Indonesia: A preliminary study

Christie Nur Andani , Adi Koesoema Aman, Herman Hariman, Bidasari Lubis

Christie Nur Andani
Department of Clinical Pathology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia. Email: andani_nihh@yahoo.com

Adi Koesoema Aman
Department of Clinical Pathology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

Herman Hariman
Department of Clinical Pathology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

Bidasari Lubis
Department of Pediatrics, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Online First: August 01, 2019 | Cite this Article
Andani, C., Aman, A., Hariman, H., Lubis, B. 2019. Cytogenetic mutation in a family with sickle-cell beta-thalassemia in North Sumatera, Medan, Indonesia: A preliminary study. Bali Medical Journal 8(2). DOI:10.15562/bmj.v8i2.1417


Background: The prevalence of  Hb S/β Thalassemia has not been widely reported, and until now, there is a lack of statistical data on the prevalence of the disease in Indonesia. In 1974, cases of β thalassemia with Hb S were found in one family in Jakarta. The aim of this study was to describe the cytogenetic mutation in a family with Hb S/β thalassemia in North Sumatera.

Methods: This was a descriptive study with a cross-sectional design conducted in one family of HbS patients with thalassemia trait, with a total of five samples. Complete blood count, hemoglobin electrophoresis examination, peripheral blood smear, PCR, and amplicon were performed to describe the hematology and cytogenetic profile of samples. Data were analyzed descriptively.

Results : The father (64 years old) suffered from HbS (HbA = 58.3%, HbS = 38.3%, HbA2 = 2.8%) with heterozygote HbS mutation type. The mother (36 years old) suffered from β-thalassemia trait (HbA = 93.8, HbF = 1.2%, HbA2 = 5%) with β-thalassemia heterozygote IVS1-nt5 mutation type. The first child (male, 18 years old) suffered from HbS/β thalassemia (HbA = 25.9%, HbF = 22.4%, HbS = 48.2%, HbF = HbA2 = 3.5%), the second child was normal (HbA = 97.4%, HbA2 = 2.6%) and the third child (female, 10 years old ) suffered from HbS β-thalassemia (HbA = 3.3%, HbF = 25.5%, HbS = 67.6%, HbA2 = 3.6%). The first and third child had β-thalassemia with double heterozygote HbS and IVS1-nt5 mutation type.

Conclusion: Population migration between nations followed by marriage could lead to cytogenetic mutations and cause sickle-cell beta-thalassemia. The finding of double heterozygous HbS mutation and beta thalassemia need to be explored further about the patient’s fathers family.

References

Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017; 376(16): 1561 – 1573.

Strouse J. Sickle cell disease. Handb Clin Neurol. 2016; 138: 311 – 24.

Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013; 381(9861): 142 – 51.

World Health Organization. Sickle-cell anaemia: report by the Secretariat. World Health Assembly, 59. 2006. Available from: http://www.who.int/iris/handle/10665/20890

Lie-Injo LE. Sickle cell gene in Indonesia. Nature. 1957; 179(4555): 381.

Wahidijat I, Markum AH, Moeslichan S. A Case of Thalassemia-Hb S Disease in Jakarta. Paediatrica Indonesiana. 1974; 14: 128 – 131.

Kementerian Kesehatan RI. Skrining penting untuk cegah Thalassemia. 2017. [Available at http://www.depkes.go.id/article/view/17050900002/skrining-penting-untuk-cegah-thalassemia.html ] [Accessed: November 2018]

Rees DC, Gibson JS. Biomarkers in sickle cell disease. Br J Haematol. 2012; 156(4): 433 – 45.

Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004; 364(9442): 1343 – 60.

Odievre MH, Verger E, Silva-Pinto AC, Elion J. Pathophysiological insights in sickle cell disease. Indian J Med Res. 2011; 134(4): 532 – 537.

Gladwin MT. Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome. J Clin Invest. 2006; 116(9): 2330 – 2.

Forget BG, Bunn HF. Classification of the disorders of hemoglobin. Cold Spring Harb Perspect Med. 2013; 3(2): a011684.

Bain BJ. Haemoglobin and the genetic of haemoglobin synthesis. In: Bain BJ. (Ed.) Haemoglobinopathy Diagnosis. Second Edition. New Jersey: Wiley-Blackwell; 2005.

Kohne, E. Hemoglobinopathies: clinical manifestations, diagnosis, and treatment. Dtsch Arztebl Int. 2011; 108(31-32):532-40.

Schmugge M, Waye JS, Basran RK, Zurbriggen K, Frischknecht H. The Hb S/beta+-thalassemia phenotype demonstrates that the IVS-I (-2) (A>C) mutation is a mild beta-thalassemia allele. Hemoglobin. 2008; 32(3): 303–7.

Serjeant GR. The natural history of sickle cell disease. Cold Spring Harb Perspect Med. 2013; 3(10): a011783.


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0